NeOnc's Most Challenging Test Yet: Compassionate-Use Update Puts NEO100's Potential in Focus
Key Highlights
- ➤NEO100 compassionate-use case: three-year-old now breathing independently and moving legs
- ➤Abu Dhabi authorized adult and pediatric NEO100 investigational protocols in June 2026
- ➤Phase 2a NEO100 results: 48.9% six-month progression-free survival, 26.09-month median overall survival
- ➤NEO212 FDA End-of-Phase 1 Type B meeting scheduled for November 17
- ➤NeOnc completed a $15 million registered direct offering
Pediatric Case, Abu Dhabi Expansion and Board Appointment Highlight a Broader Development Strategy
Houston, Texas--(Newsfile Corp. - October 16, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) is confronting one of the most consequential tests of its investigational brain-cancer platform as it pursues treatment options for patients facing some of the most difficult challenges in neuro-oncology. The company recently reported an early clinical update involving a critically ill three-year-old boy with an aggressive brain tumor who, after receiving investigational intranasal NEO100 through NeOnc's Compassionate Care program, is breathing independently without ventilator support and beginning to move his legs. The treatment is being administered outside the company's pediatric clinical trial, following coordination with the child's physicians and the Department of Health – Abu Dhabi.
Get started
Create a free account to read the full story.